TOVX — Theriva Biologics, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 894158 ·
Last close
$0.14
Market Cap
$6.42M
52W High
$0.49
52W Low
$0.14
ADV30
3,715,754
Next earnings
—
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,295,000 -3,217,000 34,857,000 11,337,000 22,670,000
Mar 2026 300,000 — -2,127,000 -2,044,000 38,248,000 14,431,000 22,849,000
Dec 2025 0 — -2,063,000 -1,996,000 38,239,000 13,056,000 22,856,000
Sep 2025 0 — -4,440,000 -4,361,000 30,836,000 7,528,000 24,098,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,742,000
Investing CF
$-19,000
Financing CF
$12,162,000
CapEx
$-19,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.50
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-363,971,000
Inventory
—
Receivables
$1,809,000
ST Investments
—
EBIT TTM
$-11,925,000
Pretax Income TTM
$-11,617,000
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$300,000
EBITDA
$-9,699,000
Free Cash Flow
$-7,776,500
Enterprise Value
$1,567,133
Total Cash
$8,473,000
Total Debt
$3,427,000
Shares Out
45,892,668
Trailing EPS
$0.73
Book Value
$0.23
ROE
-99.8%
ROA
-19.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -24,051,000 -23,739,000 38,239,000 22,856,000 15,383,000 -16,669,000
Dec 2024 0 -19,427,000 -25,653,000 35,352,000 16,285,000 19,067,000 -16,937,000
Dec 2023 0 -21,431,000 -18,349,000 55,219,000 15,522,000 39,697,000 -18,996,000
Dec 2022 0 -21,581,000 -19,685,000 71,861,000 17,297,000 54,564,000 -19,082,000

TTM Snapshot

Revenues TTM
$516,000
NetIncome TTM
$-13,128,000
OpCashFlow TTM
—
Assets (Latest)
$34,857,000
Forward EPS
$-0.20

Peers — same industry

TickerNameMarket CapLastDaily %
APRE Aprea Therapeutics, Inc. $6.43M $0.45 —
ENVB Enveric Biosciences, Inc. $6.31M $1.41 —
TPST Tempest Therapeutics, Inc. $6.54M $0.33 —
CVKD Cadrenal Therapeutics, Inc. $6.71M $1.88 —
SNGX SOLIGENIX, INC. $6.11M $0.28 —

News headlines (Yahoo Finance, 1h cache)

Theriva Biologics: Q3 Earnings Snapshot
2026-11-12 13:09 · Yahoo
Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
2026-11-12 13:00 · Yahoo
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
2026-11-02 13:00 · Yahoo
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
2026-09-30 12:00 · Yahoo
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
2026-08-11 12:00 · Yahoo
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancre
2026-08-06 12:00 · Yahoo
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients wi
2026-07-07 12:00 · Yahoo
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
2026-06-11 12:00 · Yahoo
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
2026-04-17 20:05 · Yahoo
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
2026-05-05 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.